No Data
Sapporo Clinical Laboratory: Half Year Report - Term 61 (2024/04/01 - 2025/03/31)
Sapporo Clinical Laboratory: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)
Sony Group Corp, Asics, Mitsui Fudosan, Softbank (8th)(5541-9959)
※The calendar above is only a schedule and may be subject to change depending on the company's convenience. --------------------------------------- November 8th (Friday) <5541> Ohira Gold <5631> Nisshin Steel <5644> Metal Art <5706> Mitsui Gold <5711> Mitsubishi Ma <5727> Houg Titanium <5759> Nihon Denka <5816> Onamba <5830>
KDDI announces a 2.3% increase in operating profit in the second quarter to 573 billion yen, along with a share buyback and split.
KDDI<9433> announced its financial results for the second quarter of the fiscal year ending March 2025, with revenue increasing by 2.8% year-on-year to 2 trillion 855.7 billion 13 million yen, and operating profit increasing by 2.3% to 573 billion 86 million yen. The non-communications sectors such as enterprise digital transformation (DX) support services and finance performed well. The financial estimates for the fiscal year ending in March 2025 remain unchanged. Additionally, up to 100 billion yen, equivalent to 1.39% of the total number of issued shares (excluding treasury stock), is 2800.
Sapporo Clinical Laboratory: “Notice regarding revisions to earnings forecasts for the second quarter (interim period) of the fiscal year ending March 31, 2025
Itochu's operating profit for the first quarter increased by 13.9% to 190.5 billion yen.
Itochu (8001) announced its first quarter results for the March 2025 fiscal year, with revenue of 3.598918 trillion yen, a 7.5% increase compared to the same period of the previous year, while operating profit increased by 13.9% to 190.539 billion yen.
No Data
No Data